JT received his PhD in Chemical Engineering from the University of California Berkeley where he developed novel protein engineering strategies for viral gene therapy. He then completed a post-doc with Jim Wells at the University of California San Francisco where he developed a novel structure-based design platform to generate phospho-specific antibodies. He currently leads a team at Genentech in the Department of Antibody Engineering focused on collaboratively discovering novel biology and transformative drugs. His group seeks to advance new therapies to patients through the development of new technologies to aid in target discovery, drug challenging targets, and overcoming drug delivery barriers.